UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 2, 2010
Omni Bio Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)
| Colorado | 000-52530 | 20-8097969 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 5350 South Roslyn, Suite 430, Greenwood Village, CO |
80111 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (303) 867-3415
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 3.02 | Unregistered Sales of Equity Securities. |
On December 2, 2010, Omni Bio Pharmaceutical, Inc. (the “Company”) issued 725,000 shares of its common stock to BOCO Investments, LLC (“BOCO”) in connection with BOCO’s exercise of a warrant originally issued to BOCO in a private placement completed on March 31, 2009. The exercise price of the warrant was $0.25 per share, resulting in cash proceeds of $181,000 to the Company.
The shares issued upon the exercise of BOCO’s warrant were issued by the Company in reliance upon an exemption from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.
Item 8.01 Other Events.
The information set forth in Item 3.02 of this Form 8-K is incorporated by reference into this Item 8.01.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Omni Bio Pharmaceutical, Inc. |
||
Date: December 3, 2010
|
By: /s/ Robert C. Ogden | |
| Robert C. Ogden Chief Financial Officer |
3